QMENTA launches Central Review to address the longitudinal consistency problem that derails long-duration oncology and CNS trials
Discover what's new in QMENTA Platform 4.2, including preserved manual workflows, improved DICOM performance, modern authentication, audit logging,...
Veteran CRO executive and investor brings more than 30 years of clinical research leadership and deep pharma networks to the Barcelona-based medical...
RSNA 2025 highlighted a crowded AI landscape—but also the growing complexity of multi-site imaging trials. Learn why scanner variability, protocol...
Boston, MA, March 29, 2023— QMENTA, Inc. announced today that John E. Kelly III, PhD has been appointed to the company's Board of Advisors. Dr. Kelly...
It is difficult to diagnose Parkinson’s disease, and the only way to confirm diagnosis is postmortem. The new imaging AI tools could be the answer.
In order to assure that QMENTA is a reliable trusted partner for managing your medical data, we follow the highest security standards.
Boston, MA, 29/11/21 QMENTA announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its QMENTA Platform for...
The importance of Data Protection and Data Integrity in Imaging Clinical Trials